Our Goal: Partner Success
From the start of every project, our scientists are committed to partner success. Multi-disciplinary teams work together enabling our team members to have a direct impact on each project. When a partner reaches an important milestone, the good news spreads fast across our offices and facilities in China, UK and the US.
Lycera, a private biopharmaceutical company developing novel small molecule immunomodulatory medicines for the treatment of autoimmune diseases and cancer, has worked with Pharmaron since 2009, including Lycera’s novel ATPase program which advanced to a Phase 2 study in ulcerative colitis. Pharmaron also supported Lycera’s discovery of novel immuno-oncology candidate LYC-55716. Lycera recently announced the advancement of first-in-class RORgamma Agonist LYC-55716 into phase 2a for the treatment of solid tumors.
Written with permission by Lycera.
Learn more about our small molecule services
